We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnosing Retinitis Pigmentosa by Determining the Ratio of Dolichol Variants in Plasma or Urine

By LabMedica International staff writers
Posted on 28 Oct 2013
A reliable, high-throughput, and cost-effective liquid chromatography-mass spectrometry technique for the quantitative measurement of dolichols in blood plasma or urine can unambiguously discriminate patients with retinitis pigmentosa from asymptotic carriers of the disease genes, and carriers from normal individuals.

Retinitis pigmentosa (RP) is one of the most common forms of inherited retinal degeneration. More...
This disorder is characterized by the progressive loss of photoreceptor cells and may eventually lead to blindness. There are multiple genes that, when mutated, can cause the retinitis pigmentosa phenotype. Among these mutations are the K42E and T206A mutations in the DHDDS (dehydrodolichol diphosphate synthase) gene.

Investigators at the University of Miami (FL, USA) and at Duke University (Durham, NC, USA),using liquid chromatography-mass spectrometry, observed a characteristic shortening of plasma and urinary dolichols in RP patients carrying the K42E and T206A mutations in the DHDDS gene. Dolichol-18 (D18) became the dominant dolichol species in patients compared to dolichol-19 (D19) in normal individuals.

The D18/D19 ratio was calculated and used as an index of dolichol length distribution. K42E/K42E and K42E/T206A patients were found to have significantly higher plasma and urinary D18/D19 ratios than K42E and T206A carriers. The ratios of carriers were significantly higher than normal individuals.

The methodologies and procedures used for dolichol profiling are reliable, high-throughput, and cost-effective. Dolichol profiling, complementary to genotyping, can be readily adapted as a test in the clinic for not only the diagnosis of patients but also identification of carriers with DHDDS or other genetic mutations that may impair dolichol biosynthesis.

"It is our vision that every patient who is affected with an inherited eye disease like RP should have access to a clinician who is knowledgeable about the diseases, as well as to affordable diagnostic testing and counseling," said contributing author Dr. Byron Lam, professor of ophthalmology at the University of Miami. "This diagnostic test is a powerful tool that will help in developing treatments for RP caused by DHDDS mutations."

The study was published in the September 27, 2013, online edition of the Journal of Lipid Research.

Related Links:
University of Miami
Duke University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.